Reflecting on the clinical implications, St-Pierre says that the findings support cautious use of GLP-1 RAs in selected patients with IBD when prescribed for approved metabolic indications, with appropriate counselling and monitoring. At the same time, she noted that the findings highlight substantial evidence gaps and believes future research should move beyond proxy outcomes and incorporate prospective, IBD-specific designs that integrate objective inflammatory measures with robust metabolic phenotyping. Moreover, there should be special considerations on the effects of GLP-1 RAs on body composition of patients with IBD, she adds
Researchers also value compounds capable of maintaining consistency during long-term laboratory studies
However, the optimal extent of surgical resection remains controversial, as the post-operative recurrence rate is as high as 60%
A product that smells metallic, has changed colour, or comes in clear packaging is more likely to have degraded
Pharmacological responses to Cagri and related peptides Cagri has been broadly profiled in pharmacological assays of cells transiently transfected with CTR, CTR/RAMP1 or CTR/RAMP3 21
PMID 7961718
